Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data

Contributed by: Business Wire

Images

Evan L. Tzanis, COO and EVP Head of R&D, Neuraptive Therapeutics, Inc. (Photo: Business Wire)

Business Wire embedded0

Tags

Biotechnology

Neurology

Health

Pharmaceutical

Clinical Trials

Phase 2 NEUROFUSE Study

More Like This

“The NEUROFUSE Study has yielded promising early clinical results consistent with preclinical studies of NTX-001,” said Evan Tzanis, Chief Operating Officer and EVP of R&D at Neuraptive Therapeutics, Inc. (Photo: Business Wire)

Neuraptive Therapeutics, Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral Nerves

Business Wire embedded0

Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting

Evan L. Tzanis, Chief Operating Officer and EVP of R&D, Neuraptive Therapeutics, Inc. (Photo: Business Wire)

Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair

Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain

Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting